Drug intelligence / Profile preview

paclitaxel + docetaxel

Development stage: Unknown
Lead developer: NYU Langone Health
Modality: Small Molecules
Administration: Intravenous

Overview

Paclitaxel + docetaxel in the context of NYU Langone Health refers to the taxane chemotherapy component of a Phase II clinical trial (NCT03742986) investigating neoadjuvant treatment for inflammatory breast cancer (IBC). In this study, patients receive either paclitaxel or docetaxel (depending on HER2 status and clinician choice) in combination with the immunotherapy nivolumab, followed by doxorubicin and cyclophosphamide. Both agents are small molecule microtubule stabilizers that inhibit cell division by binding to tubulin. The trial aims to improve pathological complete response rates in this aggressive form of breast cancer.

Brand names: TaxolTaxotere
Other names: Taxanes

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on paclitaxel + docetaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on paclitaxel + docetaxel.

Explore the full profile